Xarelto

The Lancet demonstrate that Bayer's novel anticoagulant Xarelto® (rivaroxaban), taken as one tablet, once-daily, was significantly more effective at reducing the occurrence of venous blood clots following elective total knee replacement surgery (TKR) than twice-daily injectable, enoxaparin. 1 These results make Xarelto the only oral anticoagulant to have demonstrated superior efficacy compared to enoxaparin at its higher US-approved dosing regimen of 30mg twice-daily for venous thromboembolism (VTE) prevention in patients undergoing TKR. 1

Health News from Medical News Today 2009

Bayer expects peak sales of more than € 2 billion if Xarelto is licensed for use in every possible indication.

Chemicals Recovery Aids Bayer Natascha Divac 2010

If the drug, which J&J co-markets with Bayer AG under the brand name Xarelto, is approved for such patients, it would open up a major new market.

J&J Drug May Have New Role Ron Winslow 2011

New Brunswick, N.J.-based J&J will market the drug in the U.S. under the brand name Xarelto.

J&J wins U.S. approval for new blood thinner 2011

The staff review recommended that the agency issue a "complete response" for Xarelto, which is also known by its generic name, rivaroxaban.

Bayer, J&J Suffer FDA Setback Jennifer Corbett Dooren 2011

The panel's decision on rivaroxaban, which is sold under the brand name Xarelto in Europe, amounts to a recommendation that the agency approve the product.

FDA Panel Backs J&J, Bayer Drug 2009

Bayer currently sells rivaroxaban under the brand name Xarelto in Europe where it was recently approved.

Antiblood-Clot Pill Could Cut Heart Problems, Study Says 2008

That study followed 14,264 patients who took either rivaroxaban (brand name Xarelto) or warfarin (sold as Coumadin and other brand names).

NPR Topics: News 2011

That study followed 14,264 patients who took either rivaroxaban (brand name Xarelto) or warfarin (sold as Coumadin and other brand names).

NPR Topics: News 2011

A Food and Drug Administration advisory panel voted 9-2 on Thursday to recommend approval of the once-a-day anti-clotting pill, called Xarelto.

FOXNews.com 2011